



Feb 28, 2022

James Love  
Director  
Knowledge Ecology International  
1621 Connecticut Avenue NW, Suite 500  
Washington, DC 20009

**Subject:** Questions submitted in response to Federal Register Notice 2022-01330, entitled “Development and Commercialization of Regulatory T-Cell Therapies for the Treatment of Multiple Sclerosis (MS)”

Dear Mr. Love,

We confirm receipt of your questions dated Jan 27, 2022, and comments dated February 9, 2022, regarding the Federal Register Notice at F.R. Vol.87, No. 16 (page 3832), entitled “Development and Commercialization of Regulatory T-Cell Therapies for the Treatment of Multiple Sclerosis (MS),” published on January 25, 2022.

On January 27, 2022, you asked two questions concerning this technology, its stage of development and the involvement of NIH funding to the clinical trials associated with this technology. To my knowledge, NIH has not funded any clinical trials for this technology. Funding information is available at [report.nih.gov](http://report.nih.gov). Other aspects of a proposed license are confidential. On February 9, 2022, you provided a few comments including public interest provisions. We consider all comments received during the notice period and will consider your organization’s comments.

Thank you very much!

Sincerely,

Yogikala Prabhu, Ph.D.  
Senior Technology Transfer and Patent Specialist  
Technology Transfer and Intellectual Property Office  
National Institute of Allergy and Infectious Disease/NIH